ArticleEuropean journal of neurology2024
The epidemiology and societal costs of myasthenia gravis in Norway: A non-interventional study using national registry data.
Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review.Journal of neurology · 2026Pooled it
- Myasthenia Gravis With Acetylcholine Receptor Antibodies in the Very Old: Treatment Challenges and Diagnostic Pitfalls.European journal of neurology · 2026Pooled it
- Health economic evaluations of myasthenia gravis: a systematic review.Croatian medical journal · 2026Pooled it
- Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons.Journal of comparative effectiveness research · 2025Pooled it
- Medication use trajectories in myasthenia gravis pregnancies: a population-based drug utilization study.Journal of neurology · 2026Article
- Patient Perceptions of Needs and Expectations Regarding the Current Management of Myasthenia Gravis: A Biopsychosocial Study.Neurology and therapy · 2026Article
- Disease changes and cost analysis of myasthenia gravis: a 10 years retrospective study from a reference center in Italy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Characteristics of Patients with Myasthenia Gravis in the French Rare Disease Registry.European journal of neurology · 2026Article
- Low-dose IL-2 Ameliorates Experimental Autoimmune Myasthenia Gravis in Rats by Restoring the CD4-positive Helper T-cell Balance Via the JAK/STAT5 Pathway.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- In vitro enzymatic and cell culture assays for SARS-CoV-2 main protease interaction with ambenonium.Scientific reports · 2025Article
- Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - a register-based study.Journal of neurology · 2024Article
- Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population-based registry study.European journal of neurology · 2024Article
- The epidemiology and societal costs of myasthenia gravis in Norway: A non-interventional study using national registry data.European journal of neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background and purposeWith the emergence of new treatment options for myasthenia gravis (MG), there is a need for information regarding epidemiology, healthcare utilization, and societal costs to support economic evaluation and identify eligible patients. We aimed to enhance the understanding of these factors using nationwide systematic registry data in Norway.
methodsWe received comprehensive national registry data from five Norwegian health- and work-related registries. The annual incidence and prevalence were estimated for the period 2013-2021 using nationwide hospital and prescription data. The direct, indirect (productivity losses) and intangible costs (value of lost life-years [LLY] and health-related quality of life [HRQoL]) related to MG were estimated over a period of 1 year.
resultsIn 2021, the incidence of MG ranged from 15 to 16 cases per year per million population depending on the registry used, while the prevalence varied between 208.9 and 210.3 per million population. The total annual societal costs of MG amounted to EUR 24,743 per patient, of which EUR 3592 (14.5%) were direct costs, EUR 8666 (35.0%) were productivity loss, and EUR 12,485 (50.5%) were lost value from LLY and reduced HRQoL.
conclusionThe incidence and prevalence of MG are higher than previously estimated, and the total societal costs of MG are substantial. Our findings demonstrate that productivity losses, and the value of LLY and HRQoL constitute a considerable proportion of the total societal costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.